Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Get Rating) have earned a consensus recommendation of “Hold” from the thirteen analysts that are presently covering the firm, Marketbeat reports. Two analysts have rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $101.70.
Several brokerages have recently weighed in on TNDM. StockNews.com downgraded Tandem Diabetes Care from a “hold” rating to a “sell” rating in a research note on Friday, July 1st. Lake Street Capital reduced their target price on Tandem Diabetes Care from $200.00 to $150.00 in a research note on Thursday, August 4th. Wells Fargo & Company downgraded Tandem Diabetes Care from an “overweight” rating to an “underweight” rating and reduced their target price for the stock from $82.00 to $49.00 in a research note on Tuesday, August 9th. Citigroup reduced their price objective on Tandem Diabetes Care from $107.00 to $98.00 in a research note on Thursday, August 4th. Finally, Raymond James reduced their price objective on Tandem Diabetes Care from $125.00 to $90.00 and set an “outperform” rating for the company in a research note on Thursday, August 4th.
Institutional Trading of Tandem Diabetes Care
A number of hedge funds and other institutional investors have recently modified their holdings of the business. BlackRock Inc. increased its position in shares of Tandem Diabetes Care by 0.8% during the 1st quarter. BlackRock Inc. now owns 6,531,074 shares of the medical device company’s stock worth $759,496,000 after purchasing an additional 52,436 shares during the last quarter. FMR LLC boosted its holdings in Tandem Diabetes Care by 5.7% during the 2nd quarter. FMR LLC now owns 6,466,950 shares of the medical device company’s stock valued at $382,778,000 after acquiring an additional 347,352 shares during the period. Vanguard Group Inc. boosted its holdings in Tandem Diabetes Care by 2.4% during the 1st quarter. Vanguard Group Inc. now owns 6,306,724 shares of the medical device company’s stock valued at $733,408,000 after acquiring an additional 146,577 shares during the period. Capital World Investors boosted its holdings in Tandem Diabetes Care by 4.0% during the 4th quarter. Capital World Investors now owns 3,427,129 shares of the medical device company’s stock valued at $515,851,000 after acquiring an additional 133,133 shares during the period. Finally, Invesco Ltd. boosted its holdings in Tandem Diabetes Care by 7.1% during the 1st quarter. Invesco Ltd. now owns 2,080,173 shares of the medical device company’s stock valued at $241,904,000 after acquiring an additional 137,202 shares during the period. 95.28% of the stock is owned by institutional investors and hedge funds.
Tandem Diabetes Care Trading Up 15.2 %
About Tandem Diabetes Care
Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.
- Get a free copy of the StockNews.com research report on Tandem Diabetes Care (TNDM)
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
- When Will the Hangover Finally Be Over for Seagate Technology?
- Are These Green Energy Companies Right For Your Portfolio?
- Does Enphase Energy Have the Juice to Keep Powering Higher?
- The One Hydrogen Fuel Cell Stock To Rule Them All
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.